Ruiz-Hurtado LA, Corona-Lara JM, Salazar-Reyes JP, Villaseñor-Hidalgo R

Language: Spanish
References: 24
Page: 19-24
PDF size: 262.85 Kb.

ABSTRACT

Objective: to determine the relationship between erectile dysfunction and cardiovascular risk in patients with type 2 diabetes mellitus. Methods: analytical cross-sectional study in men with type 2 diabetes mellitus attending the outpatient clinic from July to August 2022. Sample by convenience in 95 participants, the International Index of Erectile Function (IIEF ) in its shortened version was applied. Cardiovascular risk was calculated with the Globorisk score (sensitivity 75%, specificity 60%) electronic version. For statistical analysis, the Kruskal-Wallis, Spearman correlation, and OR (p ‹0.05) were used. Results: mean age and years of living with type 2 diabetes mellitus were 59.52 and 11.65, respectively; 17.9% (n= 17) smokers, 81% (n= 77) presented moderate high cardiovascular risk, and 75.8% (n= 72) some degree of erectile dysfunction (12. 6%, n= 12, severe), of which 75% (n= 9) presented moderate cardiovascular risk, and 25% moderate high (n= 3); the identified risk factors for cardiovascular risk, in the study, were age (OR= 1.73), smoking (OR= 1.3), and erectile dysfunction (OR= 3.278). Conclusion: There was an association between the severity of erectile dysfunction, and the degree of cardiovascular risk. Age, smoking, and erectile dysfunction are risk factors associated with cardiovascular risk in patients with type 2 diabetes mellitus.

REFERENCES

1. INEGI. Comunicado de prensa núm. [Internet].[Citado 2023 feb 4]. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2022/EDR/EDR2021_10.pdf

2. UpToDate. Overview of peripheral artery diseasein patients with diabetes mellitus [Internet]. [Citado2023 feb 4]. Disponible en: https://www.uptodate.com

3. Federación Mexicana de Diabetes. El continuo cardiorenal [Internet]. [Citado 2023 feb 4]. Disponi-ble en: https://fmdiabetes.org/el-continuo-cardiorenal/

4. Ayta IA, McKinlay JB, Krane RJ. The likely worldwideincrease in erectile dysfunction between 1995and 2025 and some possible policy consequences:Erectile Dysfunction. BJU. 1999;84(1):50–56.

5. Delgado-Gómez J. Disfunción Eréctil: Prevalenciade DM2 en el Primer Nivel de Atención. Rev EscMed Dr. José Sierra Flores. 2012;26(1):7-10

6. ISSSTE. ¿Disfunción eréctil? [Internet]. [Citado2023 feb 15]. Disponible en: http://www.gob.mx/issste/es/articulos/disfuncion-erectil-193172?idiom=es

7. Shin D, Pregenzer G Jr, Gardin JM. Erectile dysfunction:a disease marker for cardiovascular disease.Cardiol Rev. 2011;19(1):5-11.

8. Montorsi P, Ravagnani PM, Galli S, Rotatori F,Briganti A, Salonia A, et al. The artery size hypothesis:a macrovascular link between erectiledysfunction and coronary artery disease. Am JCardiol. 2005;96(12B):19M-23M.

9. Kessler A, Sollie S, Challacombe B, Briggs K, VanHemelrijck M. The global prevalence of erectiledysfunction: a review: Global prevalence of erectiledysfunction. BJU Int. 2019;124(4):587–99.

10. Irwin GM. Erectile dysfunction. Prim Care.2019;46(2):249–255.

11. IMSS. Diagnóstico y tratamiento de dislipidemias(hipercolesterolemia) en el adulto. Guía de PrácticaClínica. IMSS 233-09 [Internet]. [Citado 2023feb 15]. Disponible en: http://www.cenetec.salud.gob.mx/contenidos/gpc/catalogoMaestroGPC.html

12. Hernández R, Thieme T, Araos F. Adaptación yAnálisis Psicométrico de la Versión Española delÍndice Internacional de Función Eréctil (IIEF) enPoblación Chilena. Ter Psicol. 2017;35(3):223-230.

13. Zegarra L, Loza C, Pérez V. Validación psicométricadel instrumento índice Internacionalde Función Eréctil en pacientes con disfuncióneréctil en Perú. Rev Perú Med Exp Salud Publica.2011;28(3):477-83.

14. Gulayin PE, Danaei G, Gutierrez L, Poggio R,Ponzo J, Lanas F, et al. External Validation of CardiovascularRisk Scores in the Southern Cone ofLatin America: ¿Which Predicts Better? Rev ArgentCardiol. 2018;86(1):13–18.

15. Globorisk. Lab risk calculator [Internet]. [Citado2023 ene 27]. Disponible en: http://www.globorisk.org/calc/labform

16. Corona G, Rastrelli G, Isidori AM, Pivonello R,Bettocchi C, Reisman Y, et al. Erectile dysfunctionand cardiovascular risk: a review of current findings.Expert Rev Cardiovasc Ther. 18(3):155-164.

17. Kouidrat Y, Pizzol D, Cosco T, Thompson T,Carnaghi M, Bertoldo A, et al. High prevalenceof erectile dysfunction in diabetes: a systematicreview and meta-analysis of 145 studies. DiabetMed. 2017;34(9):1185–1192.

18. Feldman HA, Goldstein I, Hatzichristou DG,Krane RJ, McKinlay JB. Impotence and itsmedical and psychosocial correlates: results ofthe Massachusetts Male Aging Study. J Urol.

19. 1994;151(1):54-61.19. Ramírez-Ramos JK, Borboa-García C, Gabriela-Delgado QE, Valdeolivar-Hernández MS,Hernández-Calderón J, Cervantes-Sánchez P.Prevalencia de disfunción eréctil en pacientesdiabéticos mayores de 40 años. Rev Med MD.

20. 2015;6(4):280-284.20. Espitia de la Hoz F. Disfunción eréctil, prevalenciay factores asociados, en hombres con diabetes tipo2, en el Eje Cafetero, Colombia, 2016-2019. RevUrol Colomb. 2021;30(2):91–97.

21. Uribe-Arcila JF, Colina-Vargas YA, Vélez-GaviriaM, Ceballos-Naranjo L, Cardona-Vélez J, Donado-Gómez JH. Perfil cardiovascular en pacientescon disfunción eréctil tratados en un centro de altacomplejidad en la ciudad de Medellín, Colombia.Rev Urol Colomb. 2020;29(3):148–152

22. Nutalapati S, Ghagane SC, Nerli RB, Jali MV,Dixit NS. Association of erectile dysfunctionand type II diabetes mellitus at a tertiary carecentre of south India. Diabetes Metab Syndr.2020;14(4):649–653.

23. Damaskos C, Garmpis N, Kollia P, MitsiopoulosG, Barlampa D, Drosos A, et al. Assessing cardiovascularrisk in patients with diabetes: An update.Curr Cardiol Rev. 2020;16(4):266–274.

24. Paramio-Rodríguez A, Letrán-Sarria Y, Requesen-Gálvez RL, Hernández-Nava M. Riesgo cardiovascularglobal en el consultorio 10 del PoliclínicoMártires de Calabazar. Municipio Boyeros. RevCuba Cardiol Cir Cardiovasc. 2021;27(1):1-7.